<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092439</url>
  </required_header>
  <id_info>
    <org_study_id>PBRC2019024</org_study_id>
    <nct_id>NCT04092439</nct_id>
  </id_info>
  <brief_title>The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function</brief_title>
  <acronym>WMJ</acronym>
  <official_title>The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function and Blood Flow During Hyperglycemia: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if watermelon juice supplementation improves vascular&#xD;
      dysfunction experience during hyperglycemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot study is to determine the potential for watermelon juice to&#xD;
      attenuate the reduction postprandial endothelial function and skeletal muscle microvascular&#xD;
      blood flow (MVBF) experienced during hyperglycemia.&#xD;
&#xD;
      We will attempt to answer the following hypotheses:&#xD;
&#xD;
      Hypothesis 1: Watermelon juice supplementation will attenuate the reduction in endothelial&#xD;
      dysfunction and microvascular blood flow during an oral glucose challenge.&#xD;
&#xD;
      Hypothesis 2: Watermelon juice will increase L-arginine bioavailability during hyperglycemia&#xD;
      and correlate with improved vascular response.&#xD;
&#xD;
      Exploratory Aim: The postprandial period is defined by increased sympathetic nervous system&#xD;
      activity (vasoconstriction) and NO• mediated vasodilation. Heart rate variability (HRV) is a&#xD;
      measurement of the balance of parasympathetic to sympathetic activity. We will measure HRV&#xD;
      during the oral glucose challenge to interrogate the possibility that watermelon juice can&#xD;
      modulate the balance of blood vessel constriction and relaxation during an oral glucose&#xD;
&#xD;
      Procedures Involved&#xD;
&#xD;
      There will be 1 screening visit, and 2 outpatient visits. Participants will consume&#xD;
      watermelon juice or placebo for 2 weeks. The washout period will last 2 weeks prior to the&#xD;
      cross-over to the opposite condition. Participants visits will be conducted at the Vascular&#xD;
      and Resting Metabolism Lab located in the department of kinesiology at LSU.&#xD;
&#xD;
      Screening Visit&#xD;
&#xD;
      Participants will undergo consenting and fasting blood draws to measure glucose, lipids, and&#xD;
      CBC. Vital signs (blood pressure, body weight, body composition (DXA), heart rate, etc) will&#xD;
      be measured. For DXA procedure participants will undergo a whole body scan lasting&#xD;
      approximately 10 minutes. Participants will remove all metal objects from their body and lie&#xD;
      down on the table. The legs will be secured together using two Velcro straps. The participant&#xD;
      will be instructed to remain completely still during the scan. Randomization will be&#xD;
      performed to allocate the study participant for their initial group assignment to either the&#xD;
      watermelon juice group or placebo. The initial six participants will be assigned treatment A&#xD;
      for phase 1 and treatment B for phase 2, thereafter the following 6 will be assigned&#xD;
      treatment B first then treatment A. The remaining participant will be randomly assigned&#xD;
      either treatment A or B in a counterbalanced fashion.&#xD;
&#xD;
      Daily Juice Drop-in visits&#xD;
&#xD;
      Since the required supplementation duration is 14 days participants will be provided with 2&#xD;
      days (Saturday and Sunday) worth of watermelon juice or placebo to account for days when the&#xD;
      LSU AG Center will not be open. To allow for scheduling conflicts and unforeseen&#xD;
      circumstances a 3 day period of supplementation less then or greater than the 14 periods will&#xD;
      be permitted. Participants will also be provided with juice or placebo for anticipated&#xD;
      instances where they cannot be on campus. In order to monitor compliance participants will be&#xD;
      asked return the juice container for the days where juice was consumed off premises.&#xD;
&#xD;
      Visit 2 and 3: Oral Glucose Challenge - Postprandial FMD and MVBF&#xD;
&#xD;
      Participants will arrive in morning at 6:00am fasted for 10-hours. Body composition will be&#xD;
      measured by DXA. Next, participants will rest for 30 minutes in the supine positing while&#xD;
      wearing a heart rate monitor (Zephyr, Bioharness) to measure heart rate and heart rate&#xD;
      variability. Resting metabolic rate will be measured via indirect calorimetry for 20 minutes.&#xD;
      Then fasting measures of blood glucose, FMD (ultrasound) and MVBF (near-infrared&#xD;
      spectroscopy) will be taken followed by ingestion of 75 g of glucose (glucola). An IV line&#xD;
      will be placed in the participants arm vein for blood draw purposes and will remain there&#xD;
      throughout the testing. A blood sample will be drawn, and then the participant will drink a&#xD;
      sugar solution consisting of 75 grams of glucose. Blood will be drawn at specific times after&#xD;
      you consume the drink. Each blood sample will be about 1 tablespoon. (6 tablespoons total for&#xD;
      the test). During the IV procedure, a small amount of the participant's own blood (less than&#xD;
      1 teaspoon) will immediately be returned into your vein through the IV after each specimen is&#xD;
      collected. Blood will be drawn at minute 15, 30, 60, 90, 120 minutes. Postprandial&#xD;
      measurements of FMD and MVBF will be taken at 30, 60, 90, and 120 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>Two weeks</time_frame>
    <description>Flow mediated dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Blood Flow</measure>
    <time_frame>Two weeks</time_frame>
    <description>microvascular blood flow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Watermelon juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100% watermelon juice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fructose matched control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Watermelon Juice</intervention_name>
    <description>100% Watermelon Juice</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Watermelon juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable and willing to give written informed consent and understand inclusion and&#xD;
             exclusion criteria.&#xD;
&#xD;
          2. 18-40 years of age&#xD;
&#xD;
          3. BMI between 18-29.9 kg/m2&#xD;
&#xD;
          4. Willing to allow researchers to draw blood and conduct imaging (DXA) for research&#xD;
             purposes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence or self-reported history of type 1 or 2 diabetes mellitus&#xD;
&#xD;
          2. Self-reported family history of type 2 diabetes (first degree relative with type 2&#xD;
             diabetes)&#xD;
&#xD;
          3. Evidence or self-report history of deep vein thrombosis, pulmonary embolism,&#xD;
             cardiovascular, peripheral vascular, cerebral vascular, pulmonary, or renal disease&#xD;
&#xD;
          4. Allergy to watermelon&#xD;
&#xD;
          5. Use of medication known to influence study outcomes, such as:&#xD;
&#xD;
               1. Insulin&#xD;
&#xD;
               2. Anti-diabetics (metformin)&#xD;
&#xD;
               3. Corticosteroids&#xD;
&#xD;
               4. Beta-blockers&#xD;
&#xD;
               5. Anti-coagulates&#xD;
&#xD;
          6. Use of supplements known to influence study outcomes, such as;&#xD;
&#xD;
               1. Beta-alanine&#xD;
&#xD;
               2. L-arginine&#xD;
&#xD;
               3. L-citrulline&#xD;
&#xD;
          7. Active smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy D Allerton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baena-Díez JM, Peñafiel J, Subirana I, Ramos R, Elosua R, Marín-Ibañez A, Guembe MJ, Rigo F, Tormo-Díaz MJ, Moreno-Iribas C, Cabré JJ, Segura A, García-Lareo M, Gómez de la Cámara A, Lapetra J, Quesada M, Marrugat J, Medrano MJ, Berjón J, Frontera G, Gavrila D, Barricarte A, Basora J, García JM, Pavone NC, Lora-Pablos D, Mayoral E, Franch J, Mata M, Castell C, Frances A, Grau M; FRESCO Investigators. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis. Diabetes Care. 2016 Nov;39(11):1987-1995. Epub 2016 Aug 4.</citation>
    <PMID>27493134</PMID>
  </reference>
  <reference>
    <citation>Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9. doi: 10.1056/NEJMoa1000367. Erratum in: N Engl J Med. 2011 Sep 1;365(9):869.</citation>
    <PMID>21121834</PMID>
  </reference>
  <reference>
    <citation>Avogaro A. Postprandial glucose: marker or risk factor? Diabetes Care. 2011 Oct;34(10):2333-5. doi: 10.2337/dc11-1442.</citation>
    <PMID>21949226</PMID>
  </reference>
  <reference>
    <citation>Enkhmaa B, Ozturk Z, Anuurad E, Berglund L. Postprandial lipoproteins and cardiovascular disease risk in diabetes mellitus. Curr Diab Rep. 2010 Feb;10(1):61-9. doi: 10.1007/s11892-009-0088-4.</citation>
    <PMID>20425069</PMID>
  </reference>
  <reference>
    <citation>Keske MA, Premilovac D, Bradley EA, Dwyer RM, Richards SM, Rattigan S. Muscle microvascular blood flow responses in insulin resistance and ageing. J Physiol. 2016 Apr 15;594(8):2223-31. doi: 10.1113/jphysiol.2014.283549. Epub 2015 Jan 12. Review.</citation>
    <PMID>25581640</PMID>
  </reference>
  <reference>
    <citation>Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E123-9.</citation>
    <PMID>12791603</PMID>
  </reference>
  <reference>
    <citation>Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996 Mar 1;27(3):567-74.</citation>
    <PMID>8606266</PMID>
  </reference>
  <reference>
    <citation>Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993 Dec;88(6):2510-6.</citation>
    <PMID>8080489</PMID>
  </reference>
  <reference>
    <citation>Tessari P, Cecchet D, Cosma A, Vettore M, Coracina A, Millioni R, Iori E, Puricelli L, Avogaro A, Vedovato M. Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy. Diabetes. 2010 Sep;59(9):2152-9. doi: 10.2337/db09-1772. Epub 2010 May 18.</citation>
    <PMID>20484137</PMID>
  </reference>
  <reference>
    <citation>Förstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem. 2006 Dec;387(12):1521-33. Review.</citation>
    <PMID>17132097</PMID>
  </reference>
  <reference>
    <citation>Deveaux A, Pham I, West SG, André E, Lantoine-Adam F, Bunouf P, Sadi S, Hermier D, Mathé V, Fouillet H, Huneau JF, Benamouzig R, Mariotti F. l-Arginine Supplementation Alleviates Postprandial Endothelial Dysfunction When Baseline Fasting Plasma Arginine Concentration Is Low: A Randomized Controlled Trial in Healthy Overweight Adults with Cardiometabolic Risk Factors. J Nutr. 2016 Jul;146(7):1330-40. doi: 10.3945/jn.115.227959. Epub 2016 Jun 8.</citation>
    <PMID>27281800</PMID>
  </reference>
  <reference>
    <citation>Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006 Jan 4;295(1):58-64.</citation>
    <PMID>16391217</PMID>
  </reference>
  <reference>
    <citation>Agarwal U, Didelija IC, Yuan Y, Wang X, Marini JC. Supplemental Citrulline Is More Efficient Than Arginine in Increasing Systemic Arginine Availability in Mice. J Nutr. 2017 Apr;147(4):596-602. doi: 10.3945/jn.116.240382. Epub 2017 Feb 8.</citation>
    <PMID>28179487</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Timothy Allerton, PhD</investigator_full_name>
    <investigator_title>Postdoctoral Fellow</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

